BEIJING, Aug 29 Reuters China39;s CanSino Biologics reported a 69.5 drop in revenue for the first six months versus a year ago, joining global and domestic COVID19 vaccine makers affected by waning demand for their shots.

The decline from 2.06 billion yuan 299.8 million to 629.8 million yuan was mainly driven by weaker COVID vaccine demand as growth in global uptake slowed and price changes of CanSinoBIO39;s products, the firm said in a company filing published on Sunday.

CanSinoBIO, which sells a onedose shot in countries including China and Mexico and is seeking approval for an inhaled version of the vaccine, said halfyear net profit dropped by 98.7 yearonyear.

Earlier this month, Novavax halved its fullyear revenue forecast as it does not expect further sales of its COVID shot this year in the United States amid a global supply glut and soft demand. BioNTech reported about a 40 drop in secondquarter revenue and net profit but said its upgraded shots to be used in booster campaigns would increase demand in autumn.

Sino Biopharmaceutical, which holds 15.03 stake in CoronaVacdeveloper Sinovac Life Sciences, said earlier this month it logged 503.16 million yuan in profits from associates and a joint venture in the first half this year, down over 90 from the same period in 2021.

Shenzhen Kangtai Biological Products, which produces a COVID vaccine similar to Sinovac39;s and has obtained approval from Indonesia to sell its version of AstraZeneca39;s shot, set aside…